Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
4.980
+0.080 (1.63%)
Oct 4, 2024, 4:00 PM EDT - Market closed

Orchestra BioMed Holdings Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
2.082.763.53-0.785.7
Revenue Growth (YoY)
-52.15%-21.88%---
Cost of Revenue
0.170.190.210.20.15
Gross Profit
1.912.573.32-0.985.56
Selling, General & Admin
22.8920.2614.037.9310.83
Research & Development
37.3133.8221.9512.8913.48
Operating Expenses
60.254.0835.9820.8224.31
Operating Income
-58.29-51.51-32.66-21.8-18.75
Interest Expense
----0.93-
Interest & Investment Income
3.943.850.05-0.33
Other Non Operating Income (Expenses)
-0.01-0.29-1.350.7-0.18
EBT Excluding Unusual Items
-54.36-47.95-33.96-22.03-18.6
Gain (Loss) on Sale of Investments
-0.07-0.021.03-0.99-2.75
Other Unusual Items
-1.15-1.15-0.68--
Pretax Income
-55.58-49.12-33.61-23.01-21.36
Net Income
-55.58-49.12-33.61-23.01-21.36
Net Income to Common
-55.58-49.12-33.61-23.01-21.36
Shares Outstanding (Basic)
36331522
Shares Outstanding (Diluted)
36331522
Shares Change (YoY)
66.07%121.67%609.97%4.86%-
EPS (Basic)
-1.57-1.48-2.24-10.90-10.61
EPS (Diluted)
-1.57-1.48-2.24-10.90-10.61
Free Cash Flow
-44.71-46.21-29.88-19.7-26.72
Free Cash Flow Per Share
-1.26-1.39-1.99-9.33-13.27
Gross Margin
92.02%93.26%94.03%-97.46%
Operating Margin
-2803.61%-1866.16%-924.34%--328.81%
Profit Margin
-2673.26%-1779.71%-951.26%--374.45%
Free Cash Flow Margin
-2150.41%-1674.09%-845.74%--468.56%
EBITDA
-58-51.22-32.44-21.62-18.62
D&A For EBITDA
0.290.290.220.180.14
EBIT
-58.29-51.51-32.66-21.8-18.75
Revenue as Reported
2.082.763.53-0.785.7
Source: S&P Capital IQ. Standard template. Financial Sources.